EXPRESS MAIL NO.: <u>EV 452 774 381 US</u>

HE UNITED STATES PATENT AND TRADEMARK OFFICE

Kunz et al.

Confirmation No.:

1690

Application No.:

09/910,388

Art Unit:

1653

Filed:

July 20, 2001

Examiner:

Robinson, Hope A.

For:

THERAPEUTIC INHIBITOR

Attorney Docket No.:

10177-211-999

OF VASCULAR SMOOTH

(CAM 008563-999208)

MUSCLE CELLS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be related to patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references A01-A08, B01-B79 and C01-C184 listed on the accompanying List of References Cited by Applicants. Copies of references A01-A08 and B01-B74 are submitted herewith. Copies of references B75-B79, C01 and C03-C184 are being concurrently submitted under separate cover with Express Mail No. EV 452 773 871 US.

The above-identified application claims priority under 35 U.S.C. § 120 to U.S. Patent Application No. 09/113,733 ("the '733 application"), filed July 10, 1998, now U.S. Patent No. 6,074,659, issued June 13, 2000. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of the '626 application for copies of reference C02.

References B01-B06, B08, B12-B15, B18, B22-B27, B34-B37, B39-B41, B42-B45, B47-B49, B51, B53-B72, B74-B79, C01-C11, C13-C31, C33, C36-C45, C47-C70, C73-C76,

C78-C88, C90-C103, C105-C118, C120-C127, C129-C163, C165-C171 and C173-C184 were previously cited in the Information Disclosure Statement filed on July 20, 2001, the Supplemental Information Disclosure Statement filed on January 25, 2002, the Supplemental Information Disclosure Statement filed on March 25, 2002, and the Supplemental Information Disclosure Statement filed on June 26, 2002 and are allegedly missing from the files of the application. References A01-A08, B07, B09-B11, B16-B17, B19-B21, B28-B33, B38, B42, B46, B50, B52, B73, C12, C32, C34-C35, C46, C71-C72, C77, C89, C104, C119, C128, C164 and C172 were recently brought to the attention of Attorneys for Applicants.

Identification of the above-listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 CFR § 1.97(b), since this Supplemental Information Disclosure

Statement is being filed before the mailing date of a first Office Action on the merits, it is
believed that no fee is due in connection herewith. However, should the United States Patent
and Trademark Office determine otherwise, please charge the required fee to Jones Day

Deposit Account No. 50-3013.

Respectfully submitted,

Date: November 22, 2004

Gidon D. Stern

Reg. No.)

By:

Catharina J. Chin Eng

(Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures

EXPRESS MAIL NO.: EV 452 774 381 US

Sheet 1 of 9



LIST OF REFERENCES CITED BY APPLICANTS

(Use several sheets if necessary)


ATTY DOCKET NO. 10177-211-999	APPLICATION NO			
(Cam No. 008563-999208)	09/910,388			
APPLICANT				
Kunz et al.				
FILING DATE	GROUP			
July 20, 2001 1653				

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,391,797	07/05/83	Folkman et al.			
	A02	4,768,507	09/06/88	Fischell et al.			
	A03	5,019,096	05/28/91	Fox et al.			
	A04	5,474,563	12/12/95	Myler et al.			
	A05	5,512,055	04/30/96	Domb et al.			
	A06	5,567,417	10/22/96	Sasisekharan et al.			
	A07	5,616,608	04/01/97	Kinsella et al.			
	A08	6,403,635 B1	06/11/02	Kinsella et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
							YES	NO
	B01	EP 0 260 066	03/16/88	European				
	B02	EP 0 297 946	01/04/89	European				
	B03	EP 0 365 863	05/02/90	European				
	B04	EP 0 374 044	06/20/90	European				
	B05	EP 0 411 893	02/06/91	European				
	B06	EP 0 451 202	10/16/91	European				
	B07	EP 0 470 569 A1	08/06/91	European				
	B08	EP 0 526 102	02/03/93	European				
	B09	EP 0 543 653 A1	05/26/93	European				
	B10	EP 0 567 816 A1	04/08/93	European				
	B11	EP 0 568 310 A1	04/27/93	European				
	B12	EP 0 577 215	01/05/93	European				
	B13	EP 0 588 518	03/23/94	European			·	
	B14	EP 0 606 613	07/20/94	European				
	B15	EP 0 622 076	11/02/94	European				
	B16	EP 0 623 354 A1	11/09/94	European		-		
•	B17	EP 0 623 354 B1	10/02/02	European				
	B18	EP 0 691 130	01/10/96	European				
-	B19	EP 0-7-1-1-158-B-1-	1-2/03/03	-European-		1-		
	B20	EP 1 181 943 A1	02/27/02	European				
_	B21	WO 85/00107	01/17/85	PCT				
	B22	WO 88/10259	12/29/88	PCT			1	T



Sheet 2 of 9

3						
B23/	W9 90 01969	03/08/90	PCT			
B24	WO 90/11676	10/18/90	PCT			
B25	WO 90/12597	11/01/90	PCT			
B26	WO 90/13293	11/15/90	PCT			
B27	WO 90/13332	11/15/90	PCT			
B28	WO 91/07154	05/30/91	PCT			
B29	WO 91/10424	07/25/91	PCT			
B30	WO 91/11193	08/08/91	PCT		 	
B31	WO 91/12779	09/05/91	PCT			
B32	WO 91/12846	09/05/91	PCT			
B33	WO 91/15219	10/14/91	PCT			
B34	WO 91/15222	10/17/91	PCT			
B35	WO 91/17731	11/28/91	PCT			
B36	WO 92/08480	05/29/92	PCT			
B37	WO 92/10210	06/25/92	PCT			
B38	WO 92/11872	07/23/92	PCT			
B39	WO 92/11890	07/23/92	PCT		 	
B40	WO 92/11895	07/23/92	PCT			
B41	WO 92/12717	08/06/92	PCT			
B42	WO 92/15286	02/21/02	PCT			
B43	WO 92/18546	10/29/92	PCT			
B44	WO 92/19273	11/12/92	PCT			
B45	WO 92/21363	12/10/92	PCT			
B46	WO 93/06792	04/15/93	PCT			
B47	WO 93/07748	04/29/93	PCT			
B48	WO 93/09790	05/27/93	PCT			
B49	WO 93/11120	06/10/93	PCT		 	
B50	WO 93/16687	09/02/93	PCT			
B51	WO 93/17121	09/02/93	PCT			
B52	WO 93/17669	09/16/93	PCT			
B53	WO 93/24476	12/09/93	PCT			
B54	WO 94/03644	02/17/94	PCT			
B55	WO 94/04164	03/03/94	PCT		 	
B56	WO 94/04178	03/03/94	PCT			
B57	WO 94/07529	04/14/94	PCT			
B58	WO 94/08604	04/28/94	PCT		 	
B59	WO 94/08605	04/28/94	PCT		 	
B60	WO 94/15590	07/21/94	PCT			
B61	WO 94/15646	07/21/94	PCT	ir d		
B62	WO 94/16706	08/04/94	PCT		 	
B63	WO 94/17786	08/18/94	PCT			
B64	WO 94/18345	-08/18/94	PCT-	-	-	
B65	WO 94/18954	09/01/94	PCT			
B66	WO 94/18967	09/01/94	PCT			
B67	WO 94/18968	09/01/04	PCT			

EXPRESS MAIL NO.: EV 452 774 381 USSheet 3 of 9

1				
B	^ፕ ፖኤ		09/01/94	PCT
Bo	69 W	Q.94/19001	09/01/94	PCT
B	70 W	O 94/19003	09/01/94	PCT
B	71 W	O 94/20096	09/25/94	PCT
B	72 W	O 94/20097	09/15/94	PCT
B'	73 W	O 94/21308	09/29/94	PCT
B [*]	74 W	O 94/21679	09/29/94	PCT
B.	75 W	O 94/22436	10/13/94	PCT
B'	76 W	O 94/25020	11/10/94	PCT
B	77 W	O 94/28721	12/22/94	PCT
B.	78 W	O 95/03036	02/02/95	PCT
B'	79 W	O 95/03795	02/02/95	PCT
				·

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C01	"Cytochalasins", In: The Merck Index, Eleventh Edition, Merck & Co., Rahway NJ, 438-439 (1989).
C02	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev L/07/92
C03	Allemann, et al., "Drug Loaded Poly(Lactic Acid) Nanoparticles Produced by a Reversible Salting-out Process: Purification of an Injectable Dosage Form," Eur. J. Pharm. Biopharm., Vol. 39 (1), pp. 13-18 (1993)
C04	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor β ₁ Interleukin, and β ₂ -Microglobulin Plasma Levels," Kidney International, Vol. 40, pp. 1110-1117 (1991)
C05	Aschermann, M., "Restenosis After Percutaneous Transluminal Coronary Angioplasty Pathophysiology, New Trends in Prevention and Treatment," Cor. Vasa., 36:211-218 (1994)
C06	Assoian, et al., "Type β Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells," The Journal of Cell Biology, Vol. 102, pp. 1217-1223 (1986)
C07	Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions" Int'l J. Pharm, 52 165-171 (1989)
C08	Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," J. of Clinical Endocrinology and Metabolism, Vol. 70, No. 4, pp. 1132-35 (1990)
C09	Bamburg, James R., "Biological and Biochemical Actions of Trichothecene Mycotoxins," <i>Progress in Molecular and Subcellular Biology</i> ", (Hahn F.E., et al., ed.), Springer-Verlag, pp. 41-110) (1983)
C10	Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury," JACC, Vol. 13, No. 2, p. 252A Abstract (1989)
C11	Barbacid, et al., "Binding of [acetyl- ¹⁴ C] Trichodermin to the Peptidyl Transferase Center of Eukaryotic Ribosomes," Eur. J. Biochem. 44, pp. 437-444 (1974)
C12	Bartoli et al. "In vitro and in vivo antitumoral activity of free, and encapsulated taxol". J. Microencapsulation, 7 (2):191-197, 1990
C13	Beck, et al., "Poly(DL-Lactide-co-glycolide) /Norethisterone Microcapsules: An Injectable Biodegradable Contraceptive," Biology of Reproduction, Vol. 28, pp. 186-195 (1983)
C14	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," Breast Cancer Res. and Treatment, Vol. 12, pp. 307-310 (1988)
C15	Bogyo, et al., "Cytochalasin-β-Induced Immunosuppression of Murine Allogeneic Anti-tumor Response and the Effect of Recombinant Human Interleukin-2," Cancer Immunol. Immunother, Vol. 32, pp. 400-405 (1991)
C16	Bousquet, et al., "Effects of Cytochalasin β in Culture and in Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma," Cancer Res., Vol. 50, pp. 1431-39 (1990)
C17	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," J. Urol. Vol. 130, No. 6, pp. 1208-10 (1983)
C18	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988)
C19	Bumol, et al., "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," PNAS (USA), Vol. 79, pp. 1245-49 (1982)
C20	Butta, et al., "Induction of Transforming Growth Factor β ₁ in Human Breast Cancer in vivo Following Tamoxifen Treatment," Cancer Res. Vol. 52, pp. 4261-64 (1992)
C21	Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992)
C22	Chaldakov, et al., "Cyclic AMP-and Cytochalasin B-induced Arborization in Cultured Aortic Smooth Muscle Cells: Its Cytopharmacological Characterization," Cell Tissue Res. Vol. 255, pp. 435-442 (1989)

EXPRESS MAIL NO.: <u>EV 452 774 381 US</u>

	Cżą	Chander, et if, "Pyrrolidino-4-iodotamoxifen and 4-lodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," Cancer Research, Vol. 51, pp. 5851-5858 (1991)
	C24	Character al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the
	C2 -	Chronic Fatigue Syndrome," Cytokine, Vol. 3, No. 4, pp. 292-298 (1991)
(C25	Chapman, et al., "A Bioabsorbable Stent: Initial Experimental Results," Supplement III Cir., Vol. 82, No. 4, p. III-72 (1990)
	C26	Clowes et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery," Cir. Res. Vol. 56, No. 1, pp. 139-145 (1985)
	C27	Clowes, et al. "Mechanisms of Stenosis After Arterial Injury", Laboratory Investigation, Vol. 49, No. 2, pp. 208-215 (1983)
	C28	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - I. Smooth Muscle Growth in the Absence of Endothelium", Laboratory Investigation, Vol. 49, No. 3, pp. 327-333 (1983)
·	C29	Clowes, et al., "Kinetics of Cellular Proliferation After Arterial Injury - III, Endothelial and Smooth Muscle Growth in Chronically Denuded Vessels", Laboratory Investigation, Vol. 54, No. 3, pp. 295-303 (1986)
	C30	Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres," Pharmaceutical Research, Vol. 8, No. 6, pp. 713-720 (1991)
1	C31	Cole, R. J. et al., "The Cytochalasins", In: Handbook of Toxic Fungal Metabolics, Academic Press, New York, p. 264-265, 281-282 (1981)
	C32	Coomber and Gotlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation". Ateriosclerosis, 10 (2):215-222, 1990
	C33	Cowsar, et al., "Poly(Lactide-co-glycolide) Microcapsules for Controlled Release of Steroids," Methods in Enzymology, Vol. 112, pp. 101-117 (1985)
	C34	Cox et al., "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". Coronary Artery Disease, 3:237-248, 1992
,	C35	Cox et al., "Local Delivery of Heperin and methotrexate fails to inhibit in vivo smooth muscle cell proliferation". Circulation Suppl. 84(4):II-71, #0284, 1991
	C36	Crissman, et al., "Transformed Mammalian Cells are Deficient in Kinase-Mediated Control of Progression Through the G ₁ Phase of the Cell Cycle," PNAS (USA), Vol. 88, pp. 7580-84 (1991)
	C37	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," Journal of Immunological Methods, Vol. 158, pp. 17-25 (1993)
	C38	Danielpour, et al., "Evidence for Differential Regulator of TGFβ1 and TGFβ2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays," Annals New York Academy of Sciences, pp. 300-302
	C39	Danielpour, et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-1 and TGF-2) Secreted by Cells in Culture," Journal of Cellular Physiology, Vol. 138, pp. 79-86 (1989)
1	C40	Dasch, et al., "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," Annals New York Academy of Sciences, pp. 303-305
	C41	Detre, et al., "Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981", The New England J. of Med., Vol 318, No. 5, pp. 265-270 (1988)
	C42	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," Genetic Engineering News, pp. 7 & 19 (1993)
	C43	Ebner, et al., "Cloning of a Type 1 TGF-β Receptor and Its Effect on TGF-β Binding to the Type II Receptor," Science, Vol. 260, pp. 1344-48 (1993)
	C44	Eldridge, et al., "Biodegradable and Biocompatible Poly(DL-Lactide-CO-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid which Enhances the Level of Toxin-Neutralizing Antibodies," Infection and Immunity, 59(9):2978-2986 (1991)
	C45	Epstein, Stephen E., MD., "Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells," Cir. Vol. 84, No. 2, pp. 778-787 (1991)
	C46	Ettenson and Gotlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and Remodeling of Double-Sided In Vitro Wounds". Laboratory Investigation, Vol. 68, No. 6, pp. 722-733, 1992, United States and Canadian Academy of Pathology, Inc.
	C47	Fanelli, et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., Vol 119, No. 2, Part 1, pp. 357-368 (1990)
,	C48	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," Br. J. Pharmacol. Vol. 107, pp. 679-683 (1992)
	C49	Faxon et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", Arteriosclerosis, Vol. 4, No. 3, pp. 189-195 (1984)
	C50-	-Fay, et-al., "Effects-of-Cytochalasin-B-On-The-Uptake-of-Ascorbic-Acid-and-Glucose-By-3T3-Fibroblasts: Mechanism of Impaired Ascorbate Transport in Diabetes," <i>Life Sci.</i> , Vol. 46, pp. 619-624 (1990) (USA)
	C51	Feelisch, et al., "Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells," Biochemical and Biophysical Research Communications, Vol. 180, No. 1, pp. 286-293 (1991)

EXPRESS MAIL NO.: <u>EV 452 774 381 US</u> Sheet 5 of 9

Ħ		
	0 52	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", Exp. Mol. Pathol., 43 288-296 (1985)
	C53	Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies: JACC, 17, 758-769, (1991)
	C54	Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", Prog. Colloid and Polymer Sci., 56, 16-20 (1975)
	C55	Fulop, et al., "Age-Dependent Variations of Intralysosomal Enzyme Release from Human PMN Leukocytes Under Various Stimuli," <i>Immunobiol.</i> , Vol. 171, pp. 302-310 (1986)
	C56	Garrigues, et al., "The Melanoma Proteoglycan: Restricted Expression on Microspikes, a Specific Microdomain of the Cell Surface," J. Cell Biol. Vol. 103, pp 1699-1710 (1986)
	C57	Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", International Journal of Pharmaceutics, 69, 193-196 (1991)
	C58	Gasco, M. R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection:, Intl. J. of Pharmaceut, 62 119-123 (1990)
	C59	Glagov, et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries," New England J. of Med., Vol. 316 No. 22, p. 1371-1375 (1987)
	C60	Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to
	C61	Horseradish Peroxidase," Atherosclerosis, Vol. 65, pp. 215-225 (1987) Grainger, et al., "Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing
	C62	transforming growth factor-like activity from serum," Cardiovascular Research, Vol 27, pp. 2238-47 (1993) Grainger, et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells in
	C63	Culture by Inducing Production of Transforming Growth Factor β," Biochem J. Vol. 294, pp. 109-112 (1993) Grainger, et al., A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat
	C64	Vascular Smooth-Muscle Cells," <i>Biochem. J.</i> Vol. 277, pp. 145-151 (1991) Grainger, et al., Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth Muscle Cells," <i>Biochem. J. Vol.</i> 282, pp. 403-408 (1902)
	C65	Smooth Muscle Cells," <i>Biochem. J.</i> Vol. 283, p. 403-408 (1992) Gregory, <i>et al.</i> "Effects of Treatment with Cyclosporine, FK 506, Rapamycin, Mycophenolic Acid, or Description of the Cyclosporine of the C
	C66	Deoxyspergualin on Vascular Muscle Proliferation in Vivo," Transplantation Proceedings, 25:770-771 (1993) Hanke, et al., Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-
	C67	Weight Heparin," Circulation, Vol 85, No. 4, pp. 1548-56 (1992) Harpel, et al., "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," Proc. Natl.
	C68	Acad. Sci. USA, Vol. 86, pp. 3847-3851 (1989) Heldin, et al., "Demonstration of an Antibody Against Platelet-derived Growth Factor," Experimental Cell
	C69	Research," Vol. 136, pp. 255-261 (1981) Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols," J. of Polymer Science:
	C70	Polymer Letters Edition, Vol. 18, pp. 298-297 (1980) Henriksson, et al., "Hormonal Regulation of Serum Lp (α) Levels; J. Clin. Invest. Vol. 89, p. 1166-1171 (1992)
	C71	Hermans et al., "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet"" American Heart Journal, 122 (1) Part, 1, 171-187, 1991
	C72	Hirata et al., "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate". Arthritis and Reumatism, 32(9): 1065-1073, 1989
	C73	Hoff, et al., "Modification of Low Density Lipoprotein with 4-Hydroxynonenal Induces Uptake by Macrophages," Arteriosclerosis, Vol. 9, No. 4, pp. 538-549 (1989)
	C74	Hoffman, et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C," Int. J. Cancer, Vol. 42, pp. 382-388 (1988)
	C75	Holland, et al., "Atherogenic Levels of Low-density Lipoprotein Increase Endocytotic Activity in Cultured Human Endothelial Cells," Amer. J. of Pathology, Vol. 140, No. 3, pp. 551-558 (1992)
	C76	Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." Exp. Cell Res., 200, 358-360 (1992)
	C77	Jampel et al., "In vitro release of hydrophobic drugs from polyanhydride disks". Ophthal Surg, 23 (11):676-680, 1991
	C78	Jarvis, et al., "Allelopathic Agents from Parthenium hysterophorus and Baccharis megapotamica," Chemistry of Alleopathy, pp. 149-159 (1985)
	C79	Jarvis, et al., "Macrocylic and Other Novel Trichothecenes: Their Structure, Synthesis, and Biological Significance," Acc. Chem. Res. 15 pp. 338-395 (1982)
	C80	Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues," Supp. II Circulation, Vol. 78, No. 4, p. II-82 (1988)
	C81	Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials," Hormones, Cell Biol. and Cancer: Perspectives and Potentials, pp. 105-123 (1988)
	C82	Jung, S.M., et al., "Platelet Cytoskeletal Protein Distributions in Two Triton-Insoluble Fractions and How They are Affected by Stimulants and Reagents that Modify Cytoskeletal Protein Interactions" Thrombosis Research,



 ج.	The E
	50 775-787 (1988)
 C83 '7	Kambic, et al., "Biomaterials in Artificial Organs," Chemical & Engineering News, pp. 31-48 (1986)
 C84	Kemp et al., "The Id Gene is Activated by Serum But is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells," Biochem. J. (Great Britain), Vol. 277, pp. 285-288 (1991)
 C85	Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells" Cell, 48 417-428
C86	Koff, et al., "Negative Regulation of GI in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-β, Science, Vol. 260, pp. 536-538 (1993)
C87	Kovach, et al., "Serial Intravascular Ultrasound Studies Indicate That Chronic Recoil Is An Important Mechanism Of Restenosis Following Transcatheter Therapy," JACC Vol. 484A, Abstract 835-3 (1993)
C88	LaFont, et al., "Post-angioplasty Restenosis In The Atherosclerotic Rabbit: Proliferative Response Or Chronic Constriction?," Circulation, Vol. 88, I-521, Abstract 2806 (1993)
C89	Lambert et al., "A new method for arterial drug delivery via removable stent". JACC, 21(2):483A, #834-2, 1992
C90	Lambert, et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs," Coronary Artery Disease, Vol. 4, No. 5, pp. 469-475 (1993)
C91	Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," <i>Growth Factors and the Cardiovascular System</i> , Chapter 14 (Cummins, P. ed.), Kluwer Academic Publishers, pp. 249-260 (1993)
C92	Lefer, et al., "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β ₁ , in Feline Myocardial Ischemia and Reperfusion," PNAS (USA), Vol. 90, pp. 1018-22 (1993)
C93	Lefer, et al., "Mediation of Cardioprotection by Transforming Growth Factor-β," Science, Vol. 249, pp. 61-64 (1990)
C94	Levy, "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", Intl. J. Pharmaceut. ,66, 29-37 (1990)
C95	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580: Abstract No. 263625g (1994)
C96	Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", Biochimica et Biophysica Acta, 1042, 42-50 (1990)
C97	Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and Is Chemotactic for Smooth Muscle Cells In Vitro," Cir. Res. Vol. 74, No. 2, pp. 214-224 (1994)
C98	Lin, et al., "Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase," Cell. Vol. 68, pp. 775-785 (1992)
 C99	Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", Drug Development and Industrial Pharmacy, 16, 899-920
C100	Intraperitoneal Bolus Administration In Mice," Analytical Biochem., Vol. 161, pp. 332-340 (1987)
 C101	Hyperplasia," Circulation, Vol. 79, No. 6, pp. 1374-87 (1989)
C102	Internal Medicine, Vol. 115, No. 11, pp. 860-864 (1991)
C103	Node-Negative Breast Cancer," J. of the National Cancer Institute, Vol. 82, No. 16, pp. 1327-32 (1990)
 C104	TiPS- Nov. 1990 [Vol. 11]
C105	Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", J. Pharm. Pharmacol, 42 6p, (1990)
 C106	No. 2, pp. 308-312 (1972)
C107	Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
C108	Massagué, Joan, "The Transforming Growth Factor-B; Family", Annu. Rev. Cell Biol. Vol. 6, pp. 597-641 (1990)
C109	Transforming Growth FactMacroglobulin Inactive Complex," The J. of Cell Biology, Vol. 109, pp. 441-448 (1989)
C110	McCarroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-β (TGF-β) by Endothelial-Cells-in-Culture, Clin. Chem. Vol. 36, No. 6, pp. 1-152-(1990)-Abstract-No. 0934-
CIII	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," Carcinogenesis, Vol. 7, No. 2, pp. 193-196 (1986)
 C112	The same of the sa

EXPRESS MAIL NO.: EV 452 774 381 US Sheet 7 of 9

	- 2004 W
र्दभु3	McLean, et. c., "cDNA Sequence of Human Apolipoprotein(α) is Homologous to Plasminogen," Nature, Vol. 330, No. 6143, pp. 132-137 (1987)
C114	
	Dept. (1988)
C115	Merrilees, et al., "Synthesis of TGF-β ₁ by Vascular Endothelial Cells is Correlated with Cell Spreading," J. Vasc. Res., Vol. 29, pp. 376-384 (1992)
C116	Middlebrook, et al., "Specific Association of T-2 Toxin with Mammalian Cells," Biochem. Pharmacology, Vol. 38, No. 18, pp. 3093-3102 (1989)
C117	More et al., "A Targeted Antithrobotic Conjugate with Antiplatelet and Fibrinolytic Properties which reduces in vivo Thrombus Formation", Cardiovascular Research, 27, 2200-2204 (1993).
C118	Morisaki, et al., "Effects of Transforming Growth Factor β on Growth of Aortic Smooth Muscle Cells," Atherosclerosis, Vol. 88, pp. 227-234 (1991)
C119	Moses and Langer "Inhibitors of angiogenesis". Bio/Technology. 9:630-634, 1991
C120	Nabel, "Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall", Science, 244, 1342-1344 (1983)
C121	Naito, et al., "Vascular Endothelial Cell Migration In Vitro Roles of Cyclic Nucleotides, Calcium Ion and Cytoskeletal System," Artery, Vol. 17(1), pp. 21-31 (1989)
C122	Nakao, et al., "Calcium Dependency of Aortic Smooth Muscle Cell Migration Induced by 12-L-Hydroxy-5,8,10,14-eicosatetraenoic Acid," Atherosclerosis, Vol. 46, pp. 309-319 (1983)
C123	Nikol, et al., "Expression of Transforming Growth Factor β ₁ is Increased in Human Vascular Restenosis Lesions," J. Clin. Invest., Vol. 90, pp. 1582-92 (1992)
C124	Nunes, et al., "Vitamins C and E Improve the Response to Coronary Balloon Injury In the Pig: Effect of Vascular Remodeling," Circulation, Vol. 88, No. 4, Part 2, p. I-372 (1993)
C125	O'Brien, et al., "Osteopontin mRNA and Protein are Overexpressed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification," Cir. Vol. 88, p. I-619, Abstracts from the 66 th Scientific Sessions (1993)
C126	O'Connor-McCourt, et al., "Latent Transforming Growth Factor β in Serum: A Specific Complex with 2-Macroglobulin," The Journal of biological Chemistry, Vol. 262, No. 29, pp. 14090-14099 (1987)
C127	Ohmi, et al., "Effect of K252a, A Protein Kinase Inhibitor, on the Proliferation of Vascular Smooth Muscle Cells," Biochemical and Biophysical Research Communications, Vol. 173, No. 3, p. 976-981 (1990)
C128	O-Keefe Jr. et al., "Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty". JACC, 19(7): 1597-1600, 1992
C129	Oliveira, et al., "Isolation and Characterization of Smooth Muscle Cell Membranes," Biochimica et Biophysica Acta. Vol. 332, pp. 221-232 (1974)
C130	Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Trandermal Studies of a Model Hydrophilic Drug", J. Pharm. Pharmacol., 43, 451-454 (1991).
C131	Osipow, "Transparent Emulsion" J. Soc. Cosmetic Chemists, 277-285 (1963).
C132	Palmaz et al., "Intravascular Stents", Advances in Vascular Surgery, 1, 107-135 (1993).
C133	Pardee, et al., "Control of Cell Proliferation," Cancer, Vol. 39, pp. 2747-54 (June Supplement 1977)
C134	Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", International Journal of Pharmaceutics, 65, 1690175 (1990)
C135	Podzimek, et al., "O/W Microemulsions", J. Dispersion Science and Technology, I, 341-359 (1980)
C136	Popma, et al., "Factors Influencing Restenosis After Coronary Angioplasty", The Amer. J. of Med. Vol. 88, pp. 1-16N - 1-24N (1990)
C137	Post, et al., "Restenosis Is Partly Due To Intimal Hyperplasia And Partly To Remodeling Of The Injured Arterial Wall," European Heart J., Vol. 14, p. 201, Abstract P1164 (1993)
C138	Post, et al., "Which Part Of The Angiographic Diameter Reduction After Balloon Dilation Is Due To Intimal Hyperplasia?", JACC, Vol. 21, 36A, Abstract, 851-95 (1993)
C139	Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", International Journal of Pharmaceutics, 27, 335-348, (1985)
C140	Powell et al., "Suppression of the Vascular Response to Injury: The Role of Angiotensin-Converting Enzyme -Inhibitors", JACC, 17, 137B-142B (1991).
C141	Rauterberg, et al., "Collagens in Atherosclerotic Vessel Wall Lesions," Current Topics in Pathology, Vol. 87, pp. 163-192 (1993)
C142	Reid, et al., "Fragmentation of DNA in P388D ₁ Macrophages Exposed to Oxidized Low-density Lipoprotein," FEBS Letters, Vol. 332, No. 3, pp. 218-220 (1993)
C143	Ross, et al., "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20 th
ι,	NYJD: 1553707.1

Annua Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of Vascular Disease, J. Cell Biochem. S15C, Abstract No. G006, p. 96 (1991) Ross, Russell, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s, Nature, Vol. 362, pp. 801-09 Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant" J. Dispersion Science and Technology, 1 (2), 151-164 (1980) Sanders, et al., "Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-C146 lactide-co-glycolide) Microspheres," Journal of Pharmaceutical Sciences, Vol. 73, No. 9, pp. 1294-1297 (1984) Schatz, "A View of Vascular Stents", Circulation, 79 445-457 (1989) C147 Schlingemann, et al., Expression of the High Molecular Weight Melanoma-Associated Antigen by Pericytes C148 During Angiogenesis in Tumors and in Healing Wounds," Amer. J. Pathology, Vol. 136, No. 6, pp. 1393-1405 (1990)Schneiderman, et al., "Increased Type I Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries," PNAS (USA), Vol. 89, pp. 6998-7002 (1992) Schwartz, et al., "Maintenance of Integrity in Aortic Endothelium," Fed. Proc., Vol. 39, No. 9, pp. 2618-25 C150 Schwartz, et al., "Restenosis After Balloon Angioplasty - A Practical Proliferative Model in Porcine Coronary Arteries, Circulation, Vol. 82, No. 6, pp. 2190-2200 (1990) Schwartz, et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms," C152 JACC, Vol. 20, No. 5, pp. 1284-93 (1992) Shananhan, et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle C153 Cells," Circulation Research, Vol. 73, No. 1 (1993) Shewmon, et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease," Supplement I Cir., Vol. 86, No. 4, p. C154 1345 (1992) Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenylylacetic Acid by its Incorporation into C155 Lipid Microspheres," J. Pharm. Pharmacol. 38:118-121 (1985) Simpson, J.B., et al., "Percutaneous Coronary Atherectomy", Circulation, 78, 61st Scientific Session, Abstract C156 No. 0326, p. II-82, (1988) Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay," The Journal C157 of Cell Biology, Vol. 95, pp. 667-671 (1982) Snow, et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial C158 Smooth Muscle Cells," American J. of Pathology, Vol. 137, No. 2 (1990) Speir et al., "Potential Role of Human Cytomegalorvirus and p53 Interaction in Coronary Restenosis", Science, C159 265, 391-394 (1994) Steele, P.M. et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig C160 Model", Circulation Research, 57 105-112 (1985) Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF-\(\beta\)1 Gene," The J. of Cell Biol. Vol. 120, C161 No. 1, pp. 253-260 (1993) Suckling, Keith E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent C162 Literature," Biochem. Society Transactions, Vol. 21, pp. 660-662 (1993) Tamm, Ch. Basel, "The Antibiotic Complex of the Verrucarins and Roridins," Fortschr. Chem. Org. Naturst., C163 31:65 117 (1974) Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and C164 Rheumatism, 36 (9) Suppl.:S45, 1993 Tice, et al., "Biodegradable controlled-release parental systems" Pharmaceutical Technology, 26-35 (1984) C165 Topol, Eric J., "The Restenosis "Antitheory", Mayo Clinic Proc. Vol. 68, pp. 88-90 (1993) C166 Vanhoutte, P.M., "Hypercholesterolemia, Atherosclerosis And Release Of Endothelium-Derived Relaxing C167 Factor By Aggregating Platelets," European Heart J. Vol. 12, Supplement E. pp. 25-32 (1991) Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," Br. J. C168 Pharmacol., Vol. 109, pp. 612-617 (1993) Vijayagopal, et al., "Human Monocyte-Derived Macrophages Bind Low-Density-Lipoprotein-Proteoglycan C169 Complexes by a Receptor Different from the Low-Density-Lipoprotein Receptor," Biochem. J., Vol. 289, pp. 837-844 (1993) (GB) Vijayagopal, et al., "Lipoprotein-Proteoglycan Complexes Induce Continued Cholesteryl Ester Accumulation in C170 Foam Cells from Rabbit Atherosclerotic Lesions," J. Clin. Invest. Vol. 91, pp. 1011-18 (1993) Voisard, et al., "The In-Vitro Effect of Antineoplastic Agents on Proliferative Activity and Cytoskeletal C171 Components of Plaque-derived Smooth-muscle Cells from Human Coronary Arteries," Coronary Artery Disease, 4:935-942 (1993) Voisard, R., et al., "Search for new strategies for prevention of restenosis after angioplasty: the effect of cytostatic drugs on cell migration of re-stenosing human plaques cells in vitro". Vasa Suppl. 1992; 35: 132-3 [Article in German]

EXAMINER

EXPRESS MAIL NO.: <u>EV 452 774 381 US</u> Sheet 9 of 9

टर्स	Wakefield, et al., "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight
	Complex Containing Precursor Sequences," The Journal of Biological Chemistry, Vol. 263, No. 16, pp. 7646-7634 (1988)
C174	Wakefield, et al., "Recombinant Latent Transforming Growth Factor I Has a Longer Plasma Half-Life in Rats
	than Active Transforming Growth Factor, I, and a Different Tissue Distribution," <i>The Journal of Clinical Investigation, Inc.</i> , Vol. 86, pp. 1976-1984 (1990)
C175	Weissberg, et al., "Approaches to the development of selective inhibitors of vascular smooth muscle cell
	proliferation," Cardiovascular Res., Vol. 27, pp. 1191-98 (1993)
C176	
	Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells," <i>Atherosclerosis</i> , Vol. 85, pp. 257-262
	(1990)
C177	Weissberg, et al., Effects of TGFB on Vascular Smooth Muscle Cell Growth, Growth Factors and the
	Cardiovascular System, (Cummins, P.ed), Kluwer Academic Publishers, p. 189-205 (1993)
C178	Wight, et al., "Proteoglycans Structure and Function," Cell Biol. of Extracellular Matrix, Second Edition, edite
	by Elizabeth D. Hay, PLENUM PRESS, NEW YORK CHAPTER 2, pp. 45-78 (1991)
C179	Wight, et al., "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation," Current Opinion in Cell Biol. Vol. 4, pp. 793-801 (1992)
C180	Wight, Thomas N., "Cell Biology of Arterial Proteoglycans," Arteriosclerosis, Vol. 9, No. 1., pp. 1-20 (1989)
C181	Wilensky, et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Deliver
 	Strategy Following Angioplasty," American Heart Journal, Vol. 122, No. 4, pp. 1136-1140 (1991)
C182	Wolinsky, et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the
	Normal Canine Artery, <i>JACC</i> , Vol. 15, No. 2, pp. 475-81 (1990)
C183	Zuckerman, et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and
	TGF-β," Atherosclerosis, Vol. 96, pp. 203-214 (1992)
C184	Zukerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of E by Cholesterol-Independent
	Pathways," Atherosclerosis, Vol. 103, pp. 43-54 (1993)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.